Ginkgo Bioworks

Ginkgo Bioworks is a synthetic biology company founded in 2009 that uses computational design and fermentation to engineer microorganisms for industrial applications. The company operates a foundry model, designing and building biological systems to produce chemicals, fragrances, pharmaceuticals, and other high-value compounds. Ginkgo has grown to become one of the largest and most well-funded synthetic biology firms, with partnerships spanning cosmetics, agriculture, and pharmaceutical sectors.

The company's platform combines DNA design software, high-throughput screening, and fermentation infrastructure to accelerate the development cycle from concept to production. Ginkgo went public via SPAC merger in 2021 (ticker: DNA) and has positioned itself as a key player in the bioeconomy, aiming to make biology a programmable technology for manufacturing.